Citations

Mayo Clinic

Showing 10 of 108572 citations.

Impact of Contraception on Female Sexual Function
Casey, Petra M., MacLaughlin, Kathy L. , Faubion, Stephanie S.

Journal of Women's Health | September 13, 2016 | Volume: 26 | Issue: 3 | Pages: 207-213

10.1089/jwh.2015.5703 | PMID 27622561 Get It

Background: Sexual dysfunction is common among US women of reproductive age, many of whom use contraception. Various contraceptive methods have been associated with changes in sexual function. Methods: In this narrative review, we selected key articles based on our collective clinical experience. We summarized findings and best practice recommendations for addressing a woman's contraception and its potential relationship to sexual function. Results: Although some hormonal contraception is associated with sexual dysfunction, studies show mixed results based on route of administration and progestin component. Interestingly, nonuse of contraception also appears to be associated with sexual dysfunction and dissatisfaction. Low-dose vaginal estrogen, lubricants, and moisturizers may be used for treating vaginal dryness in the setting of hypoestrogenic states in reproductive-age women. Conclusion: A review of current contraception is appropriate for women presenting with sexual health concerns. Sexual dysfunction chronologically associated with a contraceptive may be addressed by trial of an alternative method. A multidisciplinary approach to treatment is recommended, including sex therapy, pelvic floor physical therapy, and consultation with a women's health specialist as needed.
The association between poor sleep quality and global cortical atrophy is related to age. Results from the Atahualpa Project
Brutto, Óscar H. Del , Mera, Robertino M. , Zambrano, Mauricio, Castillo, Pablo R. , Castillo, Pablo R

Sleep Science | September 13, 2016 | Volume: 09 | Issue: 03 | Pages: 147-150

10.1016/j.slsci.2016.06.004 | PMID 28123651 Get It

ABSTRACT Community-dwellers aged ≥ 60 years enrolled in the Atahualpa Project underwent brain MRI and were interviewed with the Pittsburgh Sleep Quality Index. Of 290 participants, 94 (32%) had poor sleep quality and 143 (49%) had global cortical atrophy (GCA). In a logistic regression model (adjusted for demographics, cardiovascular risk factor, severe edentulism, symptoms of depression, the MoCA score, and neuroimaging signatures of cerebrovascular damage), poor sleep quality was associated with GCA (p=0.004). A multivariate probability model showed that the probability of moderate-to-severe GCA significantly increased in individuals with poor sleep quality aged ≥ 67 years. This study provides evidence for an association between poor sleep quality and GCA in older adults and the important interaction of age in this association.
Good news and bad news
Hagler, Donald J.

Catheterization and Cardiovascular Interventions | September 13, 2016 | Volume: 88 | Issue: 3 | Pages: 444-445

10.1002/ccd.26713 | PMID 27619747 Get It

Key Points: Current delivery systems for the Sapien XT valve for the native pulmonary valve are unacceptable stiff and poorly design for implantation in the pulmonary outflow tract. This report details improvisation of the Melody Ensemble for easier pulmonary outflow tract delivery of the Sapien XT valve. The unacceptable cost of the utilization of two delivery systems for valve implantation, requires industry development of an safe, effective delivery system appropriate for the pulmonary outflow tract.
Emergency use of uridine triacetate for the prevention and treatment of life‐threatening 5‐fluorouracil and capecitabine toxicity
El‐Rayes, Bassel F. , Fakih, Marwan , Cartwright, Thomas H. , Posey, James , King, Thomas , Borstel, Reid W. von, Bamat, Michael K., Ma, Wen Wee, Wee, Wen , Saif, Muhammad Wasif , Borstel, Reid W. von, El-Rayes, Bassel F , Fakih, Marwan

Cancer | September 13, 2016 | Volume: 123 | Issue: 2 | Pages: 345-356

10.1002/cncr.30321 | PMID 27622829 Get It

BACKGROUNDIncreased susceptibility to 5‐fluorouracil (5‐FU)/capecitabine can lead to rapidly occurring toxicity caused by impaired clearance, dihydropyrimidine dehydrogenase deficiency, and other genetic variations in the enzymes that metabolize 5‐FU. Life‐threatening 5‐FU overdoses occur because of infusion pump errors, dosage miscalculations, and accidental or suicidal ingestion of capecitabine. Uridine triacetate (Vistogard) was approved in 2015 for adult and pediatric patients who exhibit early‐onset severe or life‐threatening 5‐FU/capecitabine toxicities or present with an overdose. Uridine triacetate delivers high concentrations of uridine, which competes with toxic 5‐FU metabolites.METHODSIn 2 open‐label clinical studies, patients who presented with a 5‐FU/capecitabine overdose or an early onset of severe toxicities were treated. Patients received uridine triacetate as soon as possible (most within the first 96 hours after 5‐FU/capecitabine). Outcomes included survival, resumption of chemotherapy, and safety. Their survival was compared with the survival of a historical cohort of overdose patients who received only supportive care.RESULTSA total of 137 of 142 overdose patients (96%) treated with uridine triacetate survived and had a rapid reversal of severe acute cardiotoxicity and neurotoxicity; in addition, mucositis and leukopenia were prevented, or the patients recovered from them. In the historical cohort, 21 of 25 patients (84%) died. Among the 141 uridine triacetate–treated overdose patients with a diagnosis of cancer (the noncancer patients included 6 intentional or accidental pediatric overdoses), 53 resumed chemotherapy in < 30 days (median time after 5‐FU, 19.6 days), and this indicated a rapid recovery from toxicity. Adverse reactions in patients receiving uridine triacetate included vomiting (8.1%), nausea (4.6%), and diarrhea (3.5%).CONCLUSIONSIn these studies, uridine triacetate was a safe and effective lifesaving antidote for capecitabine and 5‐FU overexposure, and it facilitated the rapid resumption of chemotherapy. Cancer 2017;123:345–356. © 2016 American Cancer Society.
Development of a high‐throughput method for real‐time assessment of cellular metabolism in intact long skeletal muscle fibre bundles
Li, Rui , Steyn, Frederik J. , Lee, Kevin , Cully, Tanya R. , Calderón, Juan C. , Ngo, Shyuan T. , Stout, Michael B, Stout, Michael B , Steyn, F J

The Journal of Physiology | September 13, 2016 | Volume: 594 | Issue: 24 | Pages: 7197-7213

10.1113/jp272988 | PMID 27619319 Get It

Key points We developed a method that allows for real‐time assessment of cellular metabolism in isolated, intact long skeletal muscle fibre bundles from adult mice. This method can be used to study changes in mitochondrial function and fuel utilisation in live skeletal muscle fibre bundles. Our method enables flexibility in experimental design and high‐throughput assessment of mitochondrial parameters in isolated skeletal muscle fibre bundles. Extensor digitorum longus (EDL) fibre bundles obtained from chronic high‐fat diet fed mice had lower basal oxygen consumption under FCCP‐induced maximal respiration, when compared to control chow‐fed mice. EDL fibre bundles obtained from chronic high‐fat diet fed mice had enhanced mitochondrial oxidation capacity under FCCP‐induced maximal respiration, when compared to control chow‐fed mice. AbstractMetabolic dysfunction in skeletal muscle contributes to the aetiology and development of muscle diseases and metabolic diseases. As such, assessment of skeletal muscle cellular bioenergetics provides a powerful means to understand the role of skeletal muscle metabolism in disease and to identify possible therapeutic targets. Here, we developed a method that allows for the real‐time assessment of cellular respiration in intact skeletal muscle fibre bundles obtained from the extensor digitorum longus (EDL) muscle of adult mice. Using this method, we assessed the contribution of ATP turnover and proton leak to basal mitochondrial oxygen consumption rate (OCR). Our data demonstrate that the mitochondria in EDL fibres are loosely coupled. Moreover, in the presence of carbonyl cyanide‐p‐trifluoromethoxyphenylhydrazone (FCCP), we show that palmitate exposure induced comparable peak OCR and higher total OCR in EDL fibre bundles when compared to pyruvate exposure, suggesting that fatty acids might be a more sustainable fuel source for skeletal muscle when mitochondria are driven to maximal respiration. Application of this method to EDL fibre bundles obtained from chronic high‐fat diet fed mice revealed lower basal OCR and enhanced mitochondrial oxidation capacity in the presence of FCCP when compared to the chow‐diet fed control mice. By using a 96‐well microplate format, our method provides a flexible and efficient platform to investigate mitochondrial parameters of intact skeletal muscle fibres obtained from adult mice.
Somnolence
Covassin, Naima , Somers, Virend K.

Hypertension | September 13, 2016 | Volume: 68 | Issue: 5 | Pages: 1100-1102

10.1161/hypertensionaha.116.07073 | PMID 27620397 Get It

Keeping Up With the Clock
Covassin, Naima , Singh, Prachi , Somers, Virend K. , Singh, Prachi

Hypertension | September 13, 2016 | Volume: 68 | Issue: 5 | Pages: 1081-1090

10.1161/hypertensionaha.116.06588 | PMID 27620394 Get It

Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing
Balmañà, Judith , DiGiovanni, Laura , Gaddam, Pragna, Walsh, Michael F. , Vijai, Joseph , Nathanson, Katherine L. , Offit, Kenneth , Stadler, Zsofia K, Robson, Mark E. , Stadler, Zsofia , Garber, Judy E. , Couch, Fergus J. , Domchek, Susan M. , Joseph, Vijai , Nathanson, Katherine L , Balmaña, Judith

Journal of Clinical Oncology | September 13, 2016 | Volume: 34 | Issue: 34 | Pages: 4071-4078

10.1200/jco.2016.68.4316 | PMID 27621404 Get It

Purpose Massively parallel sequencing allows simultaneous testing of multiple genes associated with cancer susceptibility. Guidelines are available for variant classification; however, interpretation of these guidelines by laboratories and providers may differ and lead to conflicting reporting and, potentially, to inappropriate medical management. We describe conflicting variant interpretations between Clinical Laboratory Improvement Amendments–approved commercial clinical laboratories, as reported to the Prospective Registry of Multiplex Testing (PROMPT), an online genetic registry. Methods Clinical data and genetic testing results were gathered from 1,191 individuals tested for inherited cancer susceptibility and self-enrolled in PROMPT between September 2014 and October 2015. Overall, 518 participants (603 genetic variants) had a result interpreted by more than one laboratory, including at least one submitted to ClinVar, and these were used as the final cohort for the current analysis. Results Of the 603 variants, 221 (37%) were classified as a variant of uncertain significance (VUS), 191 (32%) as pathogenic, and 34 (6%) as benign. The interpretation differed among reporting laboratories for 155 (26%). Conflicting interpretations were most frequently reported for CHEK2 and ATM, followed by RAD51C, PALB2, BARD1, NBN, and BRIP1. Among all participants, 56 of 518 (11%) had a variant with conflicting interpretations ranging from pathogenic/likely pathogenic to VUS, a discrepancy that may alter medical management. Conclusions Conflicting interpretation of genetic findings from multiplex panel testing used in clinical practice is frequent and may have implications for medical management decisions.
An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia
Diouf, B , Crews, Kristine R. , Pei, D, Laumann, Kristina, Mandrekar, S. J., Luger, Selina M. , Stone, RM, We, Evans, Loh, Mignon L. , Stock, Wendy , Cheng, Christopher H.K. , Advani, Anjali S. , Larson, Richard A. , Crews, Kristine R , Loh, Mignon L

Clinical Pharmacology & Therapeutics | September 12, 2016 | Volume: 101 | Issue: 3 | Pages: 391-395

10.1002/cpt.506 | PMID 27618250 Get It

Peripheral neuropathy is a major toxicity of vincristine, yet no strategies exist for identifying adult patients at high‐risk. We used a case–control design of 48 adults receiving protocol therapy for acute lymphoblastic leukemia (ALL) who developed vincristine‐induced neuropathy (NCI grade 2–4) during treatment, and 48 matched controls who did not develop grade 2–4 neuropathy. Peripheral neuropathy was prospectively graded by National Cancer Institute (NCI) criteria. CEP72 promoter genotype (rs924607) was determined using polymerase chain reaction (PCR)‐based single nucleotide polymorphism (SNP) genotyping. Frequency of the CEP72 T/T genotype was higher in cases (31% vs. 10%, P = 0.0221) and the incidence of vincristine‐induced neuropathy (grades 2–4) was significantly higher in patients homozygous for the CEP72 T/T genotype. 75% of the 20 patients homozygous for the CEP72 T allele developed grade 2–4 neuropathy, compared to 44% of patients with CEP72 CC or CT genotype (P = 0.0221). The CEP72 polymorphism can identify adults at increased risk of vincristine‐induced peripheral neuropathy.